Summit Global Investments’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
VCM
VPM
Summit Global Investments's GILD Position: Q1 2026 in Review
Summit Global Investments reduced its Gilead Sciences (GILD) stake by 61% in Q1 2026, selling an estimated $2.63M and leaving 12,051 shares worth $1.68M. The position accounts for 0.1% of the portfolio, ranked #109.
Summit Global Investments first reported a position in GILD in Q4 2016 and has held it in 18 quarters since. The position peaked at $19.2M in Q4 2022. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Summit Global Investments held 12,051 shares of Gilead Sciences worth $1.68M as of Q1 2026.
- Summit Global Investments sold 18,810 Gilead Sciences shares in Q1 2026, an estimated $2.63M.
- Gilead Sciences made up 0.1% of Summit Global Investments's portfolio in Q1 2026, its #109 holding.
- Summit Global Investments first reported a position in Gilead Sciences in Q4 2016 and has held it in 18 quarters since.
- Summit Global Investments's Gilead Sciences position peaked at $19.2M in Q4 2022.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Summit Global Investments's 13F filing for Q1 2026, filed 7 May 2026.